metformin for COVID-19: living meta-analysis of clinical studies

Study explorer (study characteristics and results) method abbreviations pdf xlsx

display ongoing studies
Study	Ref.	Design	studied treatment	control treatment	patients	study risk of bias	sample sizes	Results
COVID 19 outpatients meta-analysis
COVID-OUT (metformin) NCT04510194		RCT	metformin	placebo	COVID 19 outpatients	some concern	663/660	suggested	inconclusive 16 % decrease in clinical deterioration (PE) with a moderate degree of certainty due to some concern in risk of bias
TOGETHER unpublished		RCT	metformin	placebo	COVID 19 outpatients	NA	217/206	inconclusive	inconclusive 15 % increase in clinical deterioration,Emergency room visit or hospitalization (PE)

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

Study explorer (study characteristics and results) method abbreviations pdf xlsx

COVID 19 outpatients meta-analysis